{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:08:09Z","timestamp":1773410889061,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00228-017-2196-4","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T22:31:16Z","timestamp":1484778676000},"page":"563-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Levodopa\/carbidopa microtablets in Parkinson\u2019s disease: a study of pharmacokinetics and blinded motor assessment"],"prefix":"10.1007","volume":"73","author":[{"given":"Marina","family":"Senek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten-Magnus","family":"Aquilonius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Askmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Medvedev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mevludin","family":"Memedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Spira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerker","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dag","family":"Nyholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"2196_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-013-0127-1","volume":"28","author":"M Senek","year":"2014","unstructured":"Senek M, Nyholm D (2014) Continuous drug delivery in Parkinson\u2019s disease. CNS Drugs 28:19\u201327","journal-title":"CNS Drugs"},{"key":"2196_CR2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord Off J Mov Disord Soc. 16:448\u2013458","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"2196_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/WNF.0b013e31823b1ffd","volume":"35","author":"D Nyholm","year":"2012","unstructured":"Nyholm D, Johansson A, Aquilonius S-M, Hellquist E, Lennern\u00e4s H, Askmark H (2012) Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 35:6\u201314","journal-title":"Clin Neuropharmacol"},{"key":"2196_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870090103","volume":"9","author":"R Marconi","year":"1994","unstructured":"Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson\u2019s disease phenomenology and pathophysiology. Mov Disord Off J Mov Disord Soc. 9:2\u201312","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"2196_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31820b570a","volume":"34","author":"J Westin","year":"2011","unstructured":"Westin J, Nyholm D, P\u00e5lhagen S et al (2011) A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol 34:61\u201365","journal-title":"Clin Neuropharmacol"},{"key":"2196_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WNF.0b013e3180ed449f","volume":"31","author":"D Nyholm","year":"2008","unstructured":"Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius S-M (2008) Enteral levodopa\/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 31:63\u201373","journal-title":"Clin Neuropharmacol"},{"key":"2196_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A et al (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J 15:316\u2013323","journal-title":"AAPS J"},{"key":"2196_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.870090416","volume":"9","author":"LV Metman","year":"1994","unstructured":"Metman LV, Hoff J, Mouradian MM, Chase TN (1994) Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa\/carbidopa. Mov Disord Off J Mov Disord Soc. 9:463\u2013465","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"2196_CR9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0404.2012.01700.x","volume":"127","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Ehrnebo M, Lewander T et al (2013) Frequent administration of levodopa\/carbidopa microtablets vs levodopa\/carbidopa\/entacapone in healthy volunteers. Acta Neurol Scand 127:124\u2013132","journal-title":"Acta Neurol Scand"},{"key":"2196_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-5173(03)00294-1","volume":"261","author":"S Bredenberg","year":"2003","unstructured":"Bredenberg S, Nyholm D, Aquilonius SM, Nystr\u00f6m C (2003) An automatic dose dispenser for microtablets\u2014a new concept for individual dosage of drugs in tablet form. Int J Pharm 261:137\u2013146","journal-title":"Int J Pharm"},{"key":"2196_CR11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","volume":"138","author":"P Svenningsson","year":"2015","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K et al (2015) Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain J Neurol 138:963\u2013973","journal-title":"Brain J Neurol"},{"key":"2196_CR12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNF.0b013e31825645d1","volume":"35","author":"D Nyholm","year":"2012","unstructured":"Nyholm D, Lewander T, Gomes-Trolin C et al (2012) Pharmacokinetics of levodopa\/carbidopa microtablets versus levodopa\/benserazide and levodopa\/carbidopa in healthy volunteers. Clin Neuropharmacol 35:111\u2013117","journal-title":"Clin Neuropharmacol"},{"key":"2196_CR13","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 25:2649\u20132653","journal-title":"Mov Disord Off J Mov Disord Soc."},{"key":"2196_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.parkreldis.2007.07.013","volume":"14","author":"MA Stacy","year":"2008","unstructured":"Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X (2008) The sensitivity and specificity of the 9-item wearing-off questionnaire. Parkinsonism Relat Disord 14:205\u2013212","journal-title":"Parkinsonism Relat Disord"},{"key":"2196_CR15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AIM, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216\u2013223","journal-title":"Neurology"},{"key":"2196_CR16","unstructured":"Wesselhoff J, Gauding J. Validering av texten \u201cTrapetskonstn\u00e4ren\u201d: analys av h\u00f6gl\u00e4sning av personer med neuromotorisk talst\u00f6rning och friska kontrollpersoner. Accessed at: http:\/\/openarchive.ki.se\/xmlui\/handle\/10616\/44955 . Accessed 8 Feb 2016"},{"key":"2196_CR17","unstructured":"R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing"},{"key":"2196_CR18","unstructured":"Acharya C, Hooker AC, Y\u0131ld\u0131z T\u00fcrky\u0131lmaz G, J\u00f6nsson S, Karlsson MO A diagnostic tool for population models using non-compartmental analysis: the ncappc package for R. Comput Methods Prog Biomed"},{"key":"2196_CR19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1468-1331.2009.02866.x","volume":"17","author":"D Nyholm","year":"2010","unstructured":"Nyholm D, Karlsson E, Lundberg M, Askmark H (2010) Large differences in levodopa dose requirement in Parkinson\u2019s disease: men use higher doses than women. Eur J Neurol 17:260\u2013266","journal-title":"Eur J Neurol"},{"key":"2196_CR20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1592\/phco.24.14.1295.43156","volume":"24","author":"JJ Th\u00e9bault","year":"2004","unstructured":"Th\u00e9bault JJ, Guillaume M, Levy R (2004) Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacother J Hum Pharmacol Drug Ther 24:1295\u20131305","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2196_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNF.0b013e3181d47849","volume":"33","author":"U Adamiak","year":"2010","unstructured":"Adamiak U, Kaldonska M, Klodowska-Duda G et al (2010) Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 33:135\u2013141","journal-title":"Clin Neuropharmacol"},{"key":"2196_CR22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00626370","volume":"41","author":"M Contin","year":"1991","unstructured":"Contin M, Riva R, Martinelli P, Albani F, Baruzzi A (1991) Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson\u2019s disease. Eur J Clin Pharmacol 41:463\u2013466","journal-title":"Eur J Clin Pharmacol"},{"key":"2196_CR23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/BF01271202","volume":"103","author":"M Murata","year":"1996","unstructured":"Murata M, Mizusawa H, Yamanouchi H, Kanazawa I (1996) Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm Vienna Austria 103:1177\u20131185","journal-title":"J Neural Transm Vienna Austria"},{"key":"2196_CR24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03506.x","volume":"28","author":"DR Robertson","year":"1989","unstructured":"Robertson DR, Wood ND, Everest H et al (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 28:61\u201369","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2196-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2196-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2196-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T01:18:10Z","timestamp":1658452690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2196-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2196-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}